Medifast Inc (MED) Files 10-K for the Fiscal Year Ended on December 31, 2019

Author's Avatar
Mar 02, 2020
Article's Main Image

Medifast Inc (MED, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Medifast Inc is a health products manufacturer in the United States. It sells products such as meal replacements, snacks, hydration products and vitamins mainly through an online platform. Medifast Inc has a market cap of $968.410 million; its shares were traded at around $82.32 with a P/E ratio of 12.80 and P/S ratio of 1.45. The dividend yield of Medifast Inc stocks is 4.12%. Medifast Inc had annual average EBITDA growth of 13.00% over the past ten years.

For the last quarter Medifast Inc reported a revenue of $170.6 million, compared with the revenue of $145.8 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $713.7 million, an increase of 42.4% from last year. For the complete 30-year financial data, please go here.. For the last five years Medifast Inc had an average revenue growth rate of 20.4% a year.

The reported diluted earnings per share was $6.43 for the year, an increase of 39.2% from previous year. Over the last five years Medifast Inc had an EPS growth rate of 43.6% a year. The Medifast Inc had a decent operating margin of 12.76%, compared with the operating margin of 13.78% a year before. The 10-year historical median operating margin of Medifast Inc is 10.75%. The profitability rank of the company is 8 (out of 10).

At the end of the fiscal year, Medifast Inc has the cash and cash equivalents of $77.0 million, compared with $81.4 million in the previous year. The long term debt was $10.4 million. The interest coverage to the debt is 4. Medifast Inc has a financial strength rank of 7 (out of 10).

At the current stock price of $82.32, Medifast Inc is traded at 48.5% discount to its historical median P/S valuation band of $159.77. The P/S ratio of the stock is 1.45, while the historical median P/S ratio is 1.46. The stock lost 32.13% during the past 12 months.

For the complete 20-year historical financial data of MED, click here.